DECIDE II

{ "short_title": "DECIDE II", "data_mode": "900", "data_mode_number": "000002393", "official_title": "Decision for or against Anti-PD-1 Treatment In Adjuvant Setting of Patients across Europe with Resected Stage IIB/IIC Melanoma", "accrual_state": "running", "therapeutic_value": "therapeutic", "therapieansatz_value": "not_applicable", "therapieintervention_value": "adjuvant", "therapielinie_value": "first", "ctgov_number": null, "eudract_number": null, "general_contact_email": "oncostudien.dermatologie@ukdd.de", "general_contact_phone": "+49 351-45819782", "hauptpruefer_dd_name": "Prof. Dr. med. Friedegund Meier", "description_laie_de": "Wissenschaftliches Ziel der Studie ist, Daten zur Lebensqualit\u00e4t und einer m\u00f6glichen nach dem chirurgischen Eingriff anschlie\u00dfenden Therapieentscheidung bei Patienten mit kutanem Melanom Stadium IIB oder IIC zu dokumentieren und auszuwerten. Die dabei erhobenen Daten dienen dazu, Einflussfaktoren und Beweggr\u00fcnde zu erfassen, die f\u00fcr oder gegen eine m\u00f6gliche Therapie nach dem chirurgischen Eingriff sprechen.", "description_laie_en": null, "description_expert_de": null, "description_expert_en": "This study is to describe the treatment rates for adjuvant anti-PD1 antibody therapy in patients with resected stage IIB/IIC cutaneous melanoma and to describe determinants for recommendations of treating physicians and/or interdisciplinary tumor boards about adjuvant treatment in Stage IIB/IIC resected melanoma. The study is also to describe motivations of declining recommended/offered adjuvant treatment among patients with resected Stage IIB/IIC melanoma.", "rechtsgrundlage_value": "BO", "phase_amg_value": null, "main_cat_id": 5, "sub_cat_id": 35 }